Business
New to The Street TV Announces its 283rd and 284th Shows with Four Corporate Interviews, Airing on Fox Business Network, Tonight, Monday, December 27, 2021, at 10:30 PM PST and Tomorrow Night, Tuesday, December 28, 2021, at 10:30 PM PST
New to The Street TV Announces its 283rd and 284th Shows with Four Corporate Interviews, Airing on Fox Business Network, Tonight, Monday, December 27, 2021, at 10:30 PM PST and Tomorrow Night, Tuesday, December 28, 2021, at 10:30 PM PST.
About this update from Starfleet Innotech Inc.
[{"type":"text","content":"\n NEW YORK, Dec. 27, 2021 (GLOBE NEWSWIRE) --  FMW Media’s New to The Street TV announces the broadcastings of its nationally syndicated shows tonight, Monday, December 27, 2021, at 10:30 PM PST and tomorrow, Tuesday night, December 28, 2021, at 10:30 PM PT on Fox Business Network. New to The Street’s 283rd TV show, airing tonight, Monday, December 27, 2021, 10:30 PM PST, on the Fox Business Network, features the following four (4) Companies and their businesses’ representatives: 1). First Wave BioPharma, Inc.’s (NASDAQ: FWBI) (formerly known as AzurRx BioPharma, Inc.) interview, Mr. James Sapirstein, Chairman, CEO & President. 2). Hapbee Technologies, Inc.’s (OTCQB: HAPBF) (TSXV: HAPB) interview, Yona Shtern, CEO. 3). Starfleet Innotech, Inc.’s (OTCPINK: SFIO) (a.k.a-Smokefree Innotec, Inc.) interview, Mr. Johnathan Oboza Petalver, CEO, The Global Academy, NZ (a division of Starfleet Innotech, Inc.). 4). Sekur’s® (a division of GlobeX Data, Ltd.) “SPECIAL SEGMENT – Weekly Hack” interview, internet privacy expert Mr. Alain Ghiai, CEO. Mr. James Sapirstein, Chief Executive Officer at First Wave BioPharma, Inc. (NASDAQ: FWBI) (formerly known as AzurRX Biopharma, Inc.), joins the New to The Street TV show tonight, Monday, December 27, 2021. Talking with TV Host Jane King., James updates viewers about this clinical-stage biopharmaceutical Company, specializing in developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. Mr. Sapirstein provides TV Anchor Jane King a comprehensive update on corporate ongoings and clinical studies in the USA and Europe. He talks about the advancements in the Company’s two proprietary technologies, adrulipase and niclosmaide, explaining the clinical processes and ongoing studies. James talks about niclosamide as a treatment for diarrhea and other COVID-19 related symptoms and the anticipated results of the study in the first half of 2022. First Wave’s is to find cures and treatments for those living with painful GI diseases. Airing tonight, Monday, December 27, 2021, the in-studio NASDAQ interview with Yona Shtern, Chief Executive Officer, Hapbee Technologies, Inc. (OTCQB: HAPBF) (TSXV: HAPB). Talking with TV Anchor Jane King, Mr. Shtern gives viewers an overview of the Hapbee Smart Wearable...